Skye Bioscience secures support agreements from Emerald Health Sciences for EHT acquisition; director resigns

Skye Bioscience, Inc.

Emerald Health Sciences (EHS) agreed to vote its EHT shares in favor of the arrangement and against any alternative proposal.
EHS also agreed to vote its Skye shares in favor of adopting the arrangement agreement.
Jim Heppell resigned as director and from all committees effective May 18, 2022, with no disagreement.
Support agreements terminate upon termination of the arrangement agreement.
Transaction was previously announced on May 11, 2022, and is subject to shareholder and regulatory approvals.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jim Heppell

Director

SKYE · Skye Bioscience, Inc.

Effective: 2022-05-18
Filed: May 23, 2022, 7:59 PM ET

On May 18, 2022, Jim Heppell resigned as a member of Skye’s board of directors, audit committee, compensation committee, and nominating and corporate governance committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jim Heppell resigned as Director at Skye Bioscience, Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 18, 2022, Jim Heppell resigned as a member of Skye’s board of directors, audit committee, compensation committee, and nominating and corporate governance committee.

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-22-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.